Is Tezpire (generic name) superior to Dupixent (dupilumab)?

From the Guidelines

There is no clear evidence that Tezepelumab (Tezspire) is superior to Dupilumab (Dupixent) as they have not been directly compared in head-to-head clinical trials. Both medications are effective biological therapies but work through different mechanisms and may be appropriate for different patients. Tezspire blocks thymic stromal lymphopoietin (TSLP), an upstream inflammatory mediator, making it effective across multiple types of severe asthma regardless of inflammatory phenotype. It is administered as a 210mg subcutaneous injection every 4 weeks. Dupixent blocks IL-4 and IL-13 signaling, targeting type 2 inflammation specifically, and is particularly effective for patients with elevated eosinophils or FeNO levels. Dupixent dosing varies by indication but typically involves 200-300mg injections every 2 weeks.

The choice between these medications should be individualized based on the patient's specific type of inflammation, comorbid conditions (like atopic dermatitis or chronic rhinosinusitis with nasal polyps, where Dupixent has additional approvals), insurance coverage, and administration preference. According to a recent study 1, Dupixent has been shown to be effective in treating moderate-to-severe atopic dermatitis, with significant improvements in itch, quality of life, and sleep. Another study 1 supports the use of Dupixent, tralokinumab, abrocitinib, baricitinib, and upadacitinib for the management of atopic dermatitis in adults.

Some key points to consider when choosing between Tezspire and Dupixent include:

• The patient's specific type of inflammation and inflammatory phenotype
• The presence of comorbid conditions, such as atopic dermatitis or chronic rhinosinusitis with nasal polyps
• Insurance coverage and administration preference
• The potential for ocular surface disorders with Dupixent, which may require additional management 1
• The favorable safety profiles of both medications, with injection site reactions being the most common side effect.

Overall, the decision to use Tezspire or Dupixent should be based on a thorough evaluation of the patient's individual needs and circumstances, and Dupixent may be a better option for patients with atopic dermatitis or other conditions that are specifically targeted by this medication.

From the Research

Comparison of Tezpire and Dupixent

There are no research papers available to directly compare Tezpire and Dupixent. However, we can look at the available evidence on Dupixent (dupilumab) to understand its effectiveness and safety profile.

Efficacy of Dupixent

• Dupixent has been shown to be effective in treating moderate-to-severe atopic dermatitis in several clinical trials 2, 3, 4, 5.
• Studies have reported significant improvements in clinical indexes, biomarker levels, and disease transcriptome with dupilumab treatment 3, 5.
• Dupixent has also been used off-label in several dermatological conditions with a favorable safety profile 6.

Safety Profile of Dupixent

• The safety profile of dupilumab has been reported to be favorable with few, reversible side effects 3, 4, 6.
• Common adverse events reported with dupilumab include eye symptoms, orofacial herpes simplex virus reactivation, and injection site reactions 3, 4.
• Dupixent has been shown to be safe in patients with malignancy and other medical comorbidities 2, 4.

Real-World Experience with Dupixent

• Real-world studies have reported the effectiveness and safety of dupilumab in patients with atopic dermatitis, including those with malignancy and other comorbidities 4.
• Dupixent has been shown to be effective in reducing disease severity and improving quality of life in patients with atopic dermatitis in real-world settings 3, 4.